The relationship between the CXCL9,10,11/CXCR3 pathways and PD-1/PD-L1 is a vital area of research, and combining this pathway with other immunotherapies improves the efficacy of tumor immunotherapy by enhancing the inhibition of tumor progression through multiple mechanisms. This evidence concerns the gene CXCR3 and neoplasm.